ecPath detects ecDNA in tumors from histopathology images

Mudra Choudhury,Lihe Liu,Anamika Yadav,Owen S Chapman,Zahra Ahmadi,Raneen Younis,Chinmay Sharma,Navansh Goel,Sunita Sridhar,Rishaan Kenkre,Aditi Dutta,Shanqing Wang,Eldad Shulman,Saugato Rahman Dhruba,Hoang Danh Tai,Kevin Tharp,Megan Paul,Denise Malicki,Kevin Yip,Eytan Ruppin,Lukas Chavez,Sanju Sinha

DOI: https://doi.org/10.1101/2024.11.13.623494

2024-11-15

Abstract:Circular extrachromosomal DNA (ecDNA) can drive tumor initiation, progression and resistance in some of the most aggressive cancers and is emerging as a promising anti-cancer target. However, detection currently requires costly whole-genome sequencing (WGS) or labor-intensive cytogenetic or FISH imaging, limiting its application in routine clinical diagnosis. To overcome this, we developed ecPath (ecDNA from histopathology), a computational method for predicting ecDNA status from routinely available hematoxylin and eosin (H&E) images. ecPath implements a deep-learning method we call transcriptomics-guided learning, which utilizes both transcriptomics and H&E images during the training phase to enable successful ecDNA prediction from H&E images alone, a task not achievable with models trained on H&E images only. It is trained on more than 6,000 tumor whole-slide images from the TCGA cohort with the best performance in predicting ecDNA status in brain and stomach tumors (average AUC=0.78). ecPath revealed that ecDNA-positive tumors are enriched with pleomorphic, larger and high-density nuclei. Testing in an independent cohort, ecPath predicted ecDNA status of 985 pediatric brain tumor patients with an AUC of 0.72. Finally, we applied ecPath to identify ecDNA-positive tumors in the TCGA cohort for which no WGS data were available. Like WGS-based ecDNA-positive labels, the predicted ecDNA-positive status also identify poor prognoses for low grade glioma patients. These results demonstrate that ecPath enables the detection of ecDNA from routinely available H&E imaging alone and help nominate aggressive tumors with ecDNA to study and target it.

Pathology